Effect of Atorvastatin on Orthodontic Tooth Movement in Male Wistar Rats

Amir Hossein MirHashemi1, Maryam Afshari2, Mojgan Alaeddini3, Shahroo Etemad-Moghadam3, Ahmadreza Dehpour4, Sedigheh Sheikhzade5, Mohammad Sadegh Ahmad Akhoundi6

1Assistant Professor, Orthodontic Department, Tehran University of Medical Sciences, Tehran, Iran
2Post Graduated Student, Orthodontic Department, Qazvin University of Medical Sciences, Qazvin, Iran
3Assistant Professor, Dental Research Center, Tehran University of Medical Sciences, Tehran, Iran
4Professor Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5Post Graduated Student, Orthodontic Department, Tehran University of Medical Sciences, Tehran, Iran
6Professor, Dental Research Center Dentistry Research Institute, Department of Orthodontic, Tehran University of Medical Sciences, Tehran, Iran

Corresponding author: M. S. Ahmad Akhoundi, Department of Orthodontic, Tehran University of Medical Sciences, Tehran, Iran
ahmadakh@tums.ac.ir
Received: 28 July 2013
Accepted: 16 October 2013

Abstract

Objectives: Statins are used as cholesterol-lowering drugs by many patients and have been recently shown to affect bone metabolism. The aim of this study was to determine the effect of atorvastatin on orthodontic tooth movement (OTM) in rats.

Materials and Methods: Thirty-six adult male Sprague-Dawley rats were randomly divided into three groups of 12 samples each. Group A, served as control with no medication while groups B and C received a daily gavage of carboxymethyl cellulose (CMC) as vehicle and atorvastatin (5 mg/kg) as test substance, respectively. In all three groups, 6mm nickel-titanium closed-coil springs were ligated between the maxillary incisors and first left molars to deliver an initial force of 60g. Tooth movement was measured following sacrifice, 21 days after appliance insertion. Root resorption, PDL width and osteoclast number were histologically evaluated and compared between the groups.

Results: The mean amount of tooth movement was 0.62 mm in group A, 0.59 mm in group B and 0.38 mm in group C. OTM reduction following administration of atorvastatin was statistically significant (p<0.05), but there was no significant difference in the studied histologic variables among the three groups (p>0.05).

Conclusion: According to the results obtained in the current study, atorvastatin appears to reduce tooth movement in rats; however its effect on osteoclasts, especially osteoclastic function, requires further investigation.

Keywords: Atorvastatin, Tooth movement, Rats

INTRODUCTION
Cholesterol biosynthesis is regulated by 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in hepatic tissues and its reduction has been successfully achieved by a class of drugs known as statins or HMG-CoA reductase inhibitors. Atorvastatin is a member of this group which in addition to
lowering cholesterol, also affects endothelial and vascular smooth muscle cells, and processes like apoptosis, angiogenesis and plaque stabilization, resulting in decreased cardiovascular events and death [1].

Modulation of bone formation and inflammation are considered among the various functions of statins [2-9] and are both key factors in orthodontic tooth movement (OTM) [10]. Therefore the hypothetical effect of these agents on OTM can be an interesting topic for further research. Previous studies have shown anabolic effects of simvastatin and lovastatin on bone formation both in vitro and in rodents [7]. Maeda et al [11] demonstrated osteoblastic differentiation and enhanced osteogenesis in MC3T3-E1 cells following simvastatin treatment and suggested angiogenesis to be involved in this process. Inhibition of the mevalonate pathway by simvastatin has been claimed to be responsible for the induction of proliferation and differentiation of human periodontal ligament cells [12]. Moreover this drug can promote osteoblastic function in culture and stimulate alveolar bone formation in rats with experimentally-induced periodontitis [13]. Additional bone-related features of statins include osteoconductivity in calvarial defects of rabbits [14] and bone formation around titanium implants following intraperitoneal injection in rat tibiae [15]. In a recent study, simvastatin was shown to enhance alveolar osteogenesis and PDL remodeling subsequent to OTM in rats. Furthermore it inhibited bone resorption by osteoclasts and was proposed as a suitable agent to promote retention [16]. Considering the osteogenic and anti-inflammatory effects of simvastatin, which are both known to influence orthodontic treatments; the aim of the present study was to investigate whether systemic administration of this drug can affect the rate of orthodontic tooth movement in rats. Similar research in the English literature dealing with this issue is sparse.

MATERIALS AND METHODS
All experiments were performed according to the US National Institute of Health (publication 85-23; revised: 1985) and approved by the ethics committee of Tehran University of Medical Sciences. Thirty-six male Sprague-Dawley rats weighing 220±20g were housed in plastic cages at 22°C±2°C temperature and a humidity of 55% with a standard 12-hour light/dark photoperiod.

The animals had free access to basic rat chow and water before the experiments. All rats were randomly divided into three groups of 12 and received orthodontic treatment followed by vehicle or drug administration or no further manipulation.

Group A consisted of control animals with no medication. Groups B and C received a daily gavage of carboxymethyl cellulose (CMC) as vehicle and 5 mg/kg of atorvastatin in CMC, respectively. The rats were weighed at the beginning of the study and daily, after appliance insertion. All animals were anesthetized by intra-peritoneal injection of 0.9mg/kg xylazine HCL and 70mg/kg ketamine. Orthodontic appliances consisted of 6-mm 0.006 ×0.022 inch NiTi closed-coil springs which were tied between the left maxillary first molars and central incisors [17] using a 0.010" ligature wire (stainless steel, Dentaurum, Ispingen, Germany) to deliver a force of 60g at 2 mm activation. A cervical notch was prepared in the palatal concavity of the incisors in the cervical third just above the gingival margin with a 0.8 mm diamond bur. To prevent slipping of the ligature wires, they were secured on the incisors by application of light-cure composite (Transbond XT,3M Unitek, Monrovia, Calif).

The incisal edges of the incisors were reduced (1.5 mm) once a week in order to preclude any possible disruption of the appliances by continuous eruption of these teeth. During orthodontic treatment, the animals were fed ground rat chow and water ad libitum.
Orthodontic tooth movement measurements
Three weeks after orthodontic force application, the rats were weighed for the last time and sacrificed by ether overdose. The interproximal distance between the left upper first and second molars represented the amount of tooth movement and was measured by a filler gauge (Mitutoyo co, Kawasaki-shi, Japan), before appliance removal.
All measurements were performed twice, by a blinded operator and their mean value was recorded as the final OTM. Intra-class correlation coefficient between the two measurements was estimated to be 0.985.

Histologic analysis
After tooth movement measurements, the maxillae were separated and immersed in 10% formalin for 5 days and decalcified in formic acid (5%) for approximately 7 days. The specimens underwent routine processing and 5μm sections were cut for hematoxylin and eosin staining. The mesio-buccal roots of the first molars were histomorphometrically analyzed on six sections with the greatest root areas and the mean of the six measurements were representative of that specimen (Figure 1).

Fig 1. Representative section of the mesio-buccal root of a rat upper first molar (hematoxylin/eosin staining; Original magnification ×40)
All calculations were performed by two observers under a double-headed light microscope (Bx-51, Olympus CO, Tokyo, Japan) equipped with a digital camera (DP25 Olympus) and analysis software (DP2-BSW, Olympus). Conflicts were resolved by consensus. The level of root resorption was determined by the number and size of the resorption lacunae. The length of the lacunae were assessed by measuring the length of a virtual line joining the edges of the defect, while the distance between this line and the deepest point of the crater was considered as “lacunae depth” [18]. Osteoclastic count as an indicator of bone resorption, was quantified by counting the large multinucleated cells with slightly basophilic cytoplasms at a magnification of ×200. PDL width was estimated at the most coronal and apical parts of the bone-root interface [19], on both mesial and distal root aspects.

Statistical analysis
One-way ANOVA followed by Tukey post-hoc test were performed to clarify the differences between the groups. Probability values of less than 0.05 were considered significant.

RESULTS
Table 1 shows the amount of tooth movement in all groups. After 3 weeks of atorvastatin administration, group A showed the most and group C showed the least amount of tooth movement.

The reduction observed in the experimental group compared to the two control groups was statistically significant (P<0.05). However according to the post-hoc test, the difference between groups A and B did not reach a significant level (P=0.89).

Descriptive histologic data are shown in tables 2 and 3. Osteoclast counts in the bone adjacent to the mesiobuccal roots of rat molars demonstrated no significant difference among the three groups (P=0.17).
Periodontal ligament width was analyzed separately for each of the locations including mesiocoronal (P=0.706), mesioapical (P=0.84), distocoronal (P=0.927) and distoapical (P=0.8) surfaces and none of them exhibited a significant difference between the groups. Neither length nor depth of the resorptive lacunae was different among the groups as measured in both mesial (P=0.832 and P=0.843, respectively) and distal (P=0.398 and P=0.499, respectively) root aspects.

**DISCUSSION**

Statins, including atorvastatin, have been suggested to affect bone metabolism at the cellular level using different pathways. The function and formation of osteoclasts, one of the target cells of these drugs, are impeded through interference of statins with the mevalonate pathway. This action is upstream of where nitrogen-containing bisphosphonates inhibit conversion of mevalonate to farnesyl-PP, which was an initial step to understanding

| Table 1. Description of tooth movement in 3 experimental groups (mm) |
|----------------------|------|------|------|------|
| Groups               | N    | Mean | SD   | Min  | Max  |
| Group A              | 12   | 0.62 | 0.22 | 0.48 | 0.76 |
| Group B              | 12   | 0.58 | 0.22 | 0.45 | 0.73 |
| Group C              | 12   | 0.37 | 0.16 | 0.27 | 0.49 |

| Table 2. Descriptive data of lacunae length and depth (micrometer) |
|---------------------|------|------|------|------|
|                     | Depth|      | Length|      |
| Group A mesial      | 19.95(29.56) |  51.4(79.12) |
| Distal              | 19.29(27.7)   |  69.14(107.9)  |
| Group B mesial      | 19.15(29.91)  |  75.2(110.9)   |
| Distal              | 17.2(27.01)   |  18.27(29.61)  |
| Group C mesial      | 18.34(25.17)  |  30.08(54.35)  |
| Distal              | 9.02(16.66)   |  20.14(36.71)  |

| Table 3. Descriptive data of PDL Width (micrometer) |
|------------------------|------|------|------|
| Mean(SD)               |      |      |      |
| Group A                | 182.58(102.23) | 134.8(43.58) | 170.31(88.49) |
| Group B                | 242.08(134.97)  | 227.32(143.22) | 225.67(113.51) |
| Group C                | 207.07(98.99)   | 128.74(61.35)  | 152.39(46.83)  |
|                        | 127.84(58.23)   | 83.01(38.14)   | 134.11(61.14)  |
the osseous effects of statins [20]. In order to further evaluate the impact of these drugs on bone remodeling, we measured OTM in a rat model following atorvastatin administration using 0.006× 0.022 NiTi closed coil springs. Previous studies have also indicated that nickel-titanium springs produce more persistent forces compared to steel springs [21] and that there is no difference in rat OTM between application of 40 or 60 g forces [22]. Despite the fact that 14 days has been reported to be adequate for completion of bone remodeling, our study period was 3 weeks to assure the long term effect of atorvastatin on osseous tissues [23]. Male rats were utilized in this experiment to reduce the effect of sex hormones on bone remodeling. According to the results obtained in the current investigation, atorvastatin decreases tooth movement in rats. Several recent studies have shown that different medications can interfere with various cell signaling pathways and as a result may affect orthodontic tooth movement [24,25]. Such information is essential to clinicians, since the expected duration of treatment might be influenced by drug usage. Considering that statins are among the most commonly prescribed pharmaceutical agents for prevention of hyperlipidemia [26] and cardiovascular diseases [27], their high intake [28] along with their effects on tooth movement might be a great concern to some clinicians. Numerous attempts have been made to explain the cellular events that take place following statin administration. This drug class is proposed to act through several mechanisms including blockade of the mevalonate pathway. Coxon and Rogers [29] showed that due to mevalonate pathway suppression, development of several isoprenoid groups are obstructed leading to disrupted vesicular fusion and impaired establishment of ruffled borders which are the resorbing unit of osteoclasts. On the other hand, some forms of statin have the ability to impede the development and function of osteoclasts which can be reversed by mevalonate and geranylgeraniol treatment [30]. In addition to their bone resorbing characteristics, statins have been shown to stimulate bone formation by increasing osteoblastic number and differentiation and also through induction of mineralization and new bone formation [7,30]. These effects may be due to increased bone morphogenetic protein-2 (BMP-2) transcription and mRNA/protein expression in bone cells, which have been demonstrated to occur after administration of most statins, except pravastatin [5,8]. BMP-2 stimulates differentiation of stem cells to osteoblast-like cells [31] and promotes differentiation of mesenchymal cells to chondrocytes and osteoblasts [32]. In confirmation, Maeda et al [33] found that simvastatin augmented the expression of BMP-2, vascular endothelial growth factor (VEGF) and alkaline phosphatase mRNA among other molecules [33]. It is noteworthy that alkaline phosphatase plays an important role in mineralization of osteoid by osteoblasts [11]. Another anabolic effect of statins on bone metabolism may be the suppression of receptor activator of nuclear factor kappa-B ligand (RANKL) expression by mediating repression of the mevalonate pathway. RANKL promotes osteoclastic differentiation and activation [34], while osteoprotegerin (OPG) inhibits RANKL, hence blocking osteoclastogenesis leading to decreased bone resorption. Atorvastatin has been shown to activate OPG generation by human osteoblasts [35]. Wong and Rabie [14] suggested employing “statin collagen grafts” to replace lost bone. When implanted into rabbit calvarial defects, these grafts induced significantly larger amounts of new bone, compared to defects filled with control material. Similarly, gingival injection [13] of simvastatin and oral gavage of atorvastatin [36] was demonstrated to augment alveolar bone formation in rats. In addition Han et al [16] reported enhanced PDL remodeling and alveolar osteogenesis following simvastatin administra-
tion which led to reduced relapse of OTM in rats. Simvastatin was proposed to be responsible for both increased bone development and decreased bone resorption by regulation of RANKL and OPG.

Our findings regarding reduced rat tooth movement following treatment with atorvastatin, support the osteogenic potential of this drug group along with its preventive effect on bone resorption. In contrast to the clinical results obtained in the present study, the histologic data were inconclusive. Osteoclast number did not differ among the groups, which may be related to technical issues, low overall counts or its actual inefficacy in this process. Increased osteoclast number is not the sole factor responsible for bone resorption, since function is regarded to be similarly important in this process. Moreover, statins have been shown to affect osteoclast activity and the formation of ruffled borders in these cells [29,30]. It could be postulated that the dose of atorvastatin used in our experiment might have affected osteoclast function and not its number. Therefore further investigation using more sophisticated methods is proposed to clarify the effect of atrovastatin on different aspects of osteoclasts.

CONCLUSION
According to the results obtained in the current investigation, atorvastatin decreases the rate of experimentally-induced tooth movement in rats. If future studies support this finding in human subjects, reduced OTM should be considered in the active phase of orthodontic treatment and the patient should be informed of the effects of this drug on treatment duration.

ACKNOWLEDGMENTS
This study has been funded and supported by Tehran University of Medical Sciences (TUMS); Grant No: 132/1313. Also, the authors wish to thank the staff of Dental Research Center of Tehran University of Medical Sciences who assisted in the conduction of this study.

REFERENCES
1- LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. JAMA. 1999 Dec;282(24): 2340-2346.
2- Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation. Curr Pharm Des. 2001 May;7(8):715-36.
3- Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002 Sep;22(9):1452-8.
4- Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation. 2002 Feb;105(6): 739-745.
5- Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, Zhang C, Lu M, Katakowski M, Feldkamp CS, Chopp M. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003 Jun;53(6): 743-751.
6- Urbich C, Dernbach E, Zeiher AM, Dommeler S. Double-edged role of statins in angiogenesis signaling. Circ Res. 2002 Apr;90(6): 737-744.
7- Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science. 1999 Dec ;286(5446): 1946-9.
8- Garrett I.R, MundyG.R. The role of statins as potential targets for bone formation. Arthritis Res. 2002;4(4):237-40.
9- Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol. 2001 Oct; 21(10):1636-41.
10- Roberts WE, Ferguson DJ. Cell kinetics of the periodontal ligament. The Biology of Tooth Movement, Norton LA, Burstone CJ.
11- Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun. 2001 Jan;280(3):874-7.

12- Yazawa H, Zimmermann B, Asami Y, Bermimoulin JP. Simvastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells. J Periodontal. 2005 Feb;76(2):295-302.

13- Seto H, Ohba H, Tokunaga K, Hama H, Horibe M, Nagata T. Topical administration of simvastatin recovers alveolar bone loss in rats. J Periodontal Res. 2008 Jun;43(3):261-7.

14- Wong RW, Rabie AB. Statin collagen grafts used to repair defects in the parietal bone of rabbits. Br J Oral Maxillofac Surg. 2003 Aug;41(4):244-8.

15- Ayukawa Y, Okamura A, Koyano K. Simvastatin promotes osteogenesis around titanium implants. Clin Oral Implants Res. 2004 Jun;15(3):346-50.

16- Han G, Chen Y, Hou J, Liu C, Chen C, Zhuang J, Meng W. Effects of simvastatin on relapse and remodeling of periodontal tissues after tooth movement in rats. Am J Orthod Dentofacial Orthop. 2010 Nov;138(5):550.e1-7.

17- Nilforoushan D, Shirazi M, Dehpour AR. The role of opioid systems on orthodontic tooth movement in cholestatic rats. Angle Orthod. 2002 Oct;72(5):476-80.

18- Sekhavat AR, Mousavizadeh K, Pakshir HR, Aslani FS. Effect of misoprostol, a prostaglandin E1 analog, on orthodontic tooth movement in rats. Am J Orthod Dentofacial Orthop. 2002 Nov;122(5):542-7.

19- Tengku B, Joseph BK, Harbrow D, Taverne AA, Symons AL. Effect of a static magnetic field on orthodontic tooth movement in the rat. Eur J Orthod. 2000 Oct;22(5):475-87.

20- Luckman SP Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998 Apr;13(4):581-9.

21- Leiker BJ, Nanda RS, Currier GF, Howes RI, Sinha PK. The effects of exogenous prostaglandins on orthodontic tooth movements in rats. Am J Orthod Dentofacial Orthop. 1995 Oct;108(4):380-8.

22- King GJ, Keeling SD, McCoy EA, Ward TH. Measuring dental drift and orthodontic tooth movement in response to various initial forces in adult rats. Am J Orthod Dentofacial Orthop. 1991 May;99(5):456-65.

23- Davidovitch Z, Finkelson MD, Steigman S, Shanfeld JL, Montgomery PC, Korostoff E. Electric currents, bone remodeling and orthodontic tooth movement: I. The effect of electric currents on periodontal cyclic nucleotides. Am J Orthod. 1980 Jan;77(1):14-32.

24- Gameiro GH, Pereira-Neto JS, Magnani MB, Nauer DF. The influence of drugs and systemic factors on orthodontic tooth movement. J Clin Orthod. 2007 Feb;41(2):73-8.

25- Tyrovola JB, Spyropoulos MN. Effects of drugs and systemic factors on orthodontic treatment. Quintessence Int. 2001 May;32(5):365-71.

26- Strandberg TE, Lehto S, Pyorala K, Kesaniemi A, Oksa H. Cholesterol lowering after participation in the Scandinavian Simvastatin Survival Study (4S) in Finland. Eur Heart J. 1997 Nov;18(11):1725-7.

27- Gradosova I, Zivna H, Palicka V, Huben a S, Svejkovska K, Zivny P. Protective effect of atorvastatin on bone tissue in orchidectomised male albino Wistar rats. Eur J Pharmacol. 2012 Mar 15;679(1-3):144-50.

28- Mundy G. Statins and their potential for osteoporosis. Bone. 2001 Dec;29(6):495-7.
29- Coxon FP, Rogers MJ. The role of prenylated small GTP-binding proteins in the regulation of osteoclast function. Calcif Tissue Int. 2003 Jan;72(1):80-4

30- Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999 Jan ;96(1):133-8.

31- Wang EA, Israel DL, Kelly S, Luxenberg DP. Bone morphogenetic protein-2 caused commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors. 1993;9(1):57-71.

32- Lieberman JR, Daluisk IA, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am. 2002 Jun;84-A(6):1032-44.

33- Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H, Horiuchi N. Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. Cell Biochem. 2004 Jun;92(3):458-71.

34- Mo H, Yeganehjoo H, Shah A, Mo WK, Soelaiman IN, Shen CL. Mevalonate-suppressive dietry isoprenoids for bone health. J Nutr Biochem. 2012 Dec;23(12):1543-51.

35- Viereck V, Gründker C, Blaschke S, Frosch KH, Schoppe M, Emons G, Hofbauer LC. Atorvastatin stimulates the production of osteoprotegrin by human osteoblasts. J Cell Biochem. 2005 Dec;96(6):1244-53.

36- Goes P, Lima AP, Melo IM, Rêgo RO, Lima V. Effects of atorvastatin in radiographic density on alveolar bone loss in wistar rats. Braz Dent J. 2010;21(3):193-8.